STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Status:
Completed
Trial end date:
2016-11-11
Target enrollment:
Participant gender:
Summary
STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating
Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone
proteins known to be critical regulators of cancer cell proliferation and survival.
Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit
ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of
STA-9090 efficacy to metastatic ocular melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Synta Pharmaceuticals Corp.